Breast and prostate cancers both progress from localized precancerous lesions to invasive disease, and they display important parallels in that progression. The shared clinical and biological features between these two tumor types create an opportunity to discover common mechanisms that drive the transition from a precancerous state to invasive cancer. The PubMed abstract summarizes work that leverages spatial and volumetric tissue analysis to interrogate this malignant transition across organ contexts.
According to the abstract, Storrs and colleagues combined volumetric reconstruction of tissue with multimodal spatial profiling. This integrated approach reconstructs tissue architecture in three dimensions and overlays complementary molecular or phenotypic readouts that preserve spatial relationships. The abstract does not provide specifics such as the spatial technologies used, sample size, tumor stages analyzed, or the exact molecular modalities profiled; those experimental details are reported in the primary article by Storrs et al.
Using the combined volumetric and spatial strategy, the authors described the precancer-to-cancer transition as a continuous three-dimensional process. This characterization emphasizes that invasion emerges through spatially and morphologically continuous changes across tissue volumes, rather than appearing as an abrupt or purely two-dimensional change observable on single histologic sections.
The study identified shared molecular programs linked to invasive behavior across breast and prostate cancers. The abstract highlights the discovery of common, cross-tumor molecular features associated with the malignant transition, underscoring potentially conserved pathways or cellular programs that accompany invasion in these distinct tissues. The abstract does not list the specific genes, pathways, or molecular signatures that were found; readers are referred to the related article for those data.
The findings have several conceptual implications:
Integrating three-dimensional tissue reconstruction with spatial molecular profiling can reveal transitional features of invasion that are not captured by conventional two-dimensional histology.
Identifying shared molecular programs across breast and prostate cancers suggests there may be conserved biological processes driving invasion that could become targets for comparative biomarker development or therapeutic investigation.
The approach supports broader use of volumetric spatial technologies in studies of tumor progression, where spatial continuity and microenvironmental context are critical to understanding malignant behavior.
The abstract itself does not detail immediate clinical applications, predictive biomarkers, or therapeutic candidates; such translational steps would require the specific molecular findings and validation reported in the primary study.
The PubMed abstract summarizes the main conceptual advance but omits many experimental details. The following were not reported in the abstract and therefore cannot be asserted here:
To evaluate robustness, reproducibility, and clinical relevance, readers should consult the full article by Storrs et al., referenced in the abstract.
Storrs and colleagues used an integrated three-dimensional approach—combining volumetric tissue reconstruction with multimodal spatial profiling—to characterize the precancer-to-cancer transition as a continuous spatial process and to identify shared molecular features associated with invasion in both breast and prostate cancers. The abstract frames a conceptual advance emphasizing the importance of spatial context and volumetric analysis for understanding malignant progression. Specific experimental details and the identities of the molecular programs are not provided in the abstract and are contained in the related full article.
References
The summary is based on the PubMed abstract for “Malignant Transition in Three Dimensions” (Zehua Jing et al., Cancer Discovery 2026) and the linked related article by Storrs et al. for the primary data, as cited in the abstract. The PubMed record lists PMID 42676100 and DOI 10.1158/2159-8290.CD-26-1266.